We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Test for Bladder Cancer Could Reduce Need for Invasive Cystoscopies

By LabMedica International staff writers
Posted on 26 Apr 2022

Each year, over 300,000 cystoscopies are carried out in the UK, however, around 80% of patients with haematuria who’ve had cystoscopy are found to have no cancers or abnormalities. More...

Now, a new urine test that can be conducted in the haematuria clinic could reduce the number of patients requiring a cystoscopy by at least 45%.

Researchers at the University of Birmingham (Birmingham, UK) have developed a new urine test for bladder cancer that could reduce the need for invasive and time-consuming diagnostic procedures. The test will use highly sensitive liquid biopsy technology to detect the presence of bladder cancer by finding DNA from tumor cells present in the urine. The biomarker panel, which consists of 443 genetic mutations that are common in bladder cancer has been validated in a deep sequencing study.

In this study, which was funded by Cancer Research UK and the Medical Research Council, the researchers used the test to analyze urine from 165 people with bladder cancer that had experienced haematuria (blood in the urine), and successfully detected the disease in 144 of them (87%). The researchers also looked at using the test in 293 patients who had already been treated for bladder cancer and were being monitored for the cancer returning. In this setting, the test returned a higher proportion of false positive results compared to when used in the haematuria clinic (37.5% vs. 15.2%), with 99 positive urine tests without a tumor being seen by cystoscopy on the same day.

However, during their follow up monitoring, the patients who had those positive results had almost 3-times higher (11% vs. 4%) rates of the cancer returning within 24 months indicating that the test could help detect recurrent disease before it is visible by cystoscopy (the camera inspection of the bladder). Further research is needed for the test to be used for surveillance. The researchers are working to turn their approach into a clinical test for patients, and will start a clinical study involving over 3,000 patients to evaluate just how powerful the test is at reducing the number of cystoscopies.

“Even though cystoscopy is good at detecting bladder cancer, it’s invasive and time consuming for patients, so we need a better way to diagnose patients,” said lead researcher Mr. Richard Bryan. “In the future our test could be an easier way to get people with bladder cancer diagnosed faster, and could mean that tens of thousands of cystoscopies on healthy patients can be avoided each year.”

“These findings show that this urine test could help diagnose bladder cancer more easily,” added Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK. “Early detection of cancer is key for improving patient outcomes and research like this could help identify the patients that need treatment soonest, while easing the pressures of diagnostic procedures on the NHS. We look forward to seeing how the test performs in the next clinical trial.”

Related Links:
University of Birmingham 


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.